REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., filing under ticker TZAC, submitted an 8-K with the SEC on November 14, 2023, reflecting activity tied to its de-SPAC transaction with Tenzing Acquisition Corp. Tenzing Acquisition Corp was a blank-check company that completed its IPO in 2021, targeting the healthcare and biopharmaceutical sector. The combined entity, Reviva Pharmaceuticals Holdings, is a clinical-stage biopharmaceutical company focused on central nervous system disorders, representing a completed business combination between the SPAC vehicle and the operating target. As of the filing date, the company was operating under the TZAC ticker on Nasdaq. For the full filing history, sponsor details, and deal timeline on TZAC and thousands of other SPACs, sign up for SpacDesk at spacdesk.com.